Stocks and Investing
Stocks and Investing
Mon, February 28, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Sun, February 27, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, February 25, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Kaplan Maintained (UTHR) at Strong Buy with Decreased Target to $203 on, Feb 25th, 2022
Matthew Kaplan of Ladenburg Thalmann, Maintained "United Therapeutics Corporation" (UTHR) at Strong Buy with Decreased Target from $231 to $203 on, Feb 25th, 2022.
Matthew has made no other calls on UTHR in the last 4 months.
There is 1 other peer that has a rating on UTHR. Out of the 1 peers that are also analyzing UTHR, all agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Julian Harrison of "BTIG" Initiated at Hold on, Friday, February 11th, 2022
Contributing Sources